H.C. Wainwright Lifts Tempus AI Price Target to $66

H.C. Wainwright has raised its price target for Tempus AI to $66 from $56, while maintaining a Buy rating.

The stock currently trades at $58.74, representing potential upside of 12% to the new target.

This decision comes after the company's acquisition of Personalis was seen as favorable due to positive Phase 3 INTerpath-001 results from Merck and Moderna.

Personalis provides genomic testing services for individualized neoantigen cancer therapy trials, with Moderna and Merck accounting for approximately 14% and 30% of Personalis’ first-half 2026 revenue.